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Hearing is one of the main ways with which one person can contact the external world; it plays 
a key role in their integration with society. 
Aim: The objective of this study was to analyze the results of the hearing, medical and genetic 
evaluation of high-risk infants who failed the newborn hearing screening. 
Materials and Methods: Clinical and experimental study. We assessed thirty-eight neonates, with ages 
between one and six months. The infants underwent the following procedures: medical interview; 
immittance testing; Brainstem Auditory Evoked Potential; Transient Evoked Otoacoustic Emission and 
otorhinolaryngological evaluation. DNA extraction from the oral mucosa was performed for genetic 
studies using the protocol method adapted from the Human Genetics Lab of the CBMEG/UNICAMP. 
Results: Regarding gender and presence of risk factors, significant statistically differences were 
not found in normal hearing infants and in those with hearing loss. Concerning gestational age, 
term infants were more affected by hearing loss. Hearing loss was identified in 58% of the sample, 
conduction hearing loss represented 31.5% (12/38) and neurossensory 28.9% of cases. There were 
none of the genetic mutations most commonly seen in cases with a genetic etiology. 










77(6)-ing.indb   784 25/11/2011   13:59:28
785
Brazilian Journal of otorhinolaryngology 77 (6) novemBer/DecemBer 2011
http://www.bjorl.org  /  e-mail: revista@aborlccf.org.br
INTRODUCTION
Hearing is one of the main forms by which indi-
viduals establish contact with the external world, and is 
thus of utmost importance for integration within society.
The estimated incidence of significant and bi-
lateral hearing loss is one to three for each thousand 
newborns at low risk for hearing loss1,2; these numbers 
increase to about two to five for each one hundred 
newborns in intensive care units (ICUs)1,3,4, or 10.2% 
as reported by Lima et al.5,6 According to the Brazilian 
Geography and Statistical Institute (IBGE) the incidence 
of hearing loss in Brazilians in the year 2000 census was 
16.7%; in the state of Sao Paulo, this rate was 16.4%7. 
Hearing loss is the most common congenital abnorma-
lity; it is more prevalent than other routinely screened 
diseases. Hearing loss is 100 times more prevalent than 
phenylketonuria and 10 times more prevalent than 
hypothyroidism8. Infant hearing loss is considered a 
serious public health issue because of its high preva-
lence and the ensuing consequences, which include 
the infant’s language, cognitive, intellectual, cultural, 
and social development9,10.
Universal neonatal hearing screening has been 
recommended as the main strategy to reduce the age at 
which a diagnosis of hearing loss may be made11,12. This 
is the first step in a neonatal hearing health program, 
and should be part of a multidisciplinary approach to 
diagnosis involving mainly speech therapists, otorhino-
laryngologists, and even geneticists at specific centers. 
After a diagnosis, interventions such as sound ampli-
fication and rehabilitation should be started. An early 
diagnosis followed by medical and phonoaudiological 
interventions may help infants to establish contact with 
the world of sound at the time of central nervous system 
plasticity in the first year of life, which will increase 
nerve connections and allow for improved results in 
auditory rehabilitation and general development of 
infants with hearing loss13,14.
A test battery with behavioral and electrophysio-
logic tests is recommended for the diagnosis of hearing 
loss, such as: observing auditory behavior relative to ca-
librated and non calibrated sounds, acoustic immittance 
testing, otoacoustic emissions, and brainstem auditory 
evoked potential (BAEP). These suggested tests help 
define the type, grade, and configuration of hearing loss, 
which result in a differential diagnosis, interventions, 
and the indication of hearing aids for sensorineural, 
mixed, or conductive hearing loss15. It is important that 
the etiology of deafness be established to define the 
prognosis and implement appropriate measures.
There are several causes of congenital hearing 
loss – those acquired during the prenatal period or wi-
thin the first days after delivery. The causes of hearing 
loss may be genetic or environmental. The etiology of 
genetic origin hearing loss may be syndromic, those 
associated with craniofacial or neck malformations, ske-
letal dysplasia, skin or ocular abnormalities, neurologic 
diseases, renal or metabolic dysfunction, and others. 
It has been estimated that 30% of cases of prelingual 
deafness are syndromic and 70% are non-syndromic16. 
Non-syndromic deafness may have several patterns 
of inheritance: linked to the X chromosome (DFN) in 
1-3% of cases; autosomal dominant forms (DFNA) in 
15% of cases; and autosomal recessive forms (DFNB) in 
80% of cases. Furthermore, there are cases of maternal 
inheritance due to mitochondrial gene mutations16. In 
developed countries, about 60% of hearing loss cases 
are genetic in origin17.
Environmental factors include congenital infec-
tions, perinatal, and postnatal factors.
Thus, the purpose of this study was to investi-
gate the results of an audiologic, otorhinolaryngologic, 
and genetic evaluation of high-risk infants that failed 
in neonatal hearing screening, taking into account the 
variables male/female sex, number of risk indicators, 
and gestational age. Hearing loss was also analyzed 
according to type, grade, affected side, and possible 
etiology.
MATERIALS AND METHODS
A cross-sectional contemporary cohort study was 
carried out. It was approved by the institutional review 
board of the Research Ethics Committee of the School of 
Medical Sciences of the University of Campinas (FCM/
UNICAMP). The reference number was 028/2008.
All infants born at the Women’s Hospital - Prof. 
Dr. José Aristodemo Pinotti – CAISM/UNICAMP that 
remained in the neonatal ICU and that failed hearing 
screening, from February 2009 to March 2010 were 
enrolled. Infants born in other hospitals or that did not 
undertake all the evaluations within the study period 
were excluded. There were 52 infants sent for a diag-
nostic assessment; this number is close to the sample 
size based on the mean monthly delivery number at the 
hospital (250 deliveries) and the number of newborns 
that are admitted into the ICU (40 per month). Thus, 
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there were 500 newborns in 12 months, of which on 
average 10% (50 infants) failed in hearing screening6. 
The hearing screening test was the automatic brainstem 
auditory evoked potential (A-BAEP). An Algo 2e color 
NATUS test equipment was used in an acoustic booth. 
Infants passed the hearing screening test when the re-
sponse was present for 35 dB bilaterally on the A-BAEP.
A staff speech therapist of the hospital Audiol-
ogy Diagnostic Laboratory carried out the audiological 
evaluation. The infants were aged 1 to 6 months when 
tested; the procedures were as follows: a clinical his-
tory, evaluation of the middle ear status, BAEP testing 
(electrophysiologic threshold and auditory pathway 
integrity), and transient otoacoustic emissions (TOAE). 
Infants slept naturally while the procedures were ap-
plied.
The clinical history was taken from family mem-
bers to gather the following data: identification, the 
hospital discharge report, and information about motor, 
auditory and language development. The JCIH18 risk 
factors were used as indicators of risk; these were also 
gathered from the neonatologist’s hospital discharge 
report.
The electrophysiologic threshold and auditory 
pathway status were assessed by BAEP using an Eclipse 
EP 25 Interacoustics device with in-ear phones. Audi-
tory pathway status was investigated with non-variable 
80 dB clicks presented 19 times per second, which 
make it possible to evaluate auditory pathways and 
identify issues up to the brainstem. The electrophysi-
ologic threshold was gathered by sloping stimuli until 
reaching the lowest stimulus intensity that caused the 
V wave to appear. The stimulus was applied twice to 
obtain a reproducible tracing and make sure the re-
sponse was present. Surface electrodes were attached 
over the right and left mastoid and the frontoparietal 
regions of infants after cleaning the skin with abrasive 
paste and applying electrolytic paste. The following 
parameters were assessed: presence of waves I, III, and 
V; absolute wave I, III, and V latencies; I-V, I-III, and 
III-V interpeak latencies; wave V amplitude relative to 
wave I amplitude; and I-V interpeak or wave V latency 
interaural difference. TOAE were measured by an ILO 
292 USBII device.
The tympanometric curve was used to evaluate 
the middle ear; the probe tone was set at 1,000 Hz and 
the ipsilateral acoustic reflex was measured from 500 
to 4,000 Hz. A 235 H, Interacoustics device was used.
Responses in each test were recorded on an-
swer sheets. Normal hearing was considered as a click 
electrophysiologic threshold under 30 dB, absolute 
and interpeak latencies within expected values for the 
gestational age19, the presence of TOAE20, a type A 
tympanometric curve, and the presence of an ipsilateral 
acoustic reflex21,22.
Infants with abnormal results in at least one 
auditory test were sent to an otorhinolaryngologist to 
be evaluated. One of the researchers supervised this 
assessment, which consisted of otoscopy to examine 
the outer ear canal and the tympanic membrane, and 
imaging if needed.
Hearing was classified as normal or impaired 
depending on the analysis of the audiologic and 
otorhinolaryngologic assessments. Hearing loss was 
classified according to the type23, the grade (Silman & 
Silverman24), and whether unilateral or bilateral. Genetic 
screening was done by DNA extraction from oral mu-
cosa sampled by the examiner after performing audi-
tory testing in infants that failed hearing screening. The 
35delG mutation was investigated in the DNA sample 
by using standardized AS-PCR at the Human Molecular 
Genetics Lab - CBMEG. (patent no. P10005340-6; test 
method for deafness of genetic origin). The PCR was 
used to search for the D(GJB6-D13S1830) and D(GJB6-
D13S1854) deletions with previously reported primers25. 
A single diagnostic test involving both deletions in the 
same PCR was done. Mitochondrial mutations were ana-
lyzed by amplifying DNAmt fragments of the MTRNR1 
gene to detect the A1555G mutation; the abovemen-
tioned primer pairs were used. Restriction analysis to 
detect mutations was applied to amplification products.
The statistical analysis was made with the SAS 
software version 9.1.3. The significance level was 5%, 
and was indicated by an asterisk (*).
RESULTS
There were 52 infants that failed hearing screen-
ing and that were referred for diagnosis. Of these, 38 
infants (73%) participated in the study and underwent 
the full diagnostic process. The remaining infants ei-
ther did not come to scheduled visits or failed to sleep 
after BAEP testing, among other factors, thereby not 
undergoing the full diagnostic procedure within the 
study period.
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DISCUSSION
Neonatal hearing screening is the main method 
to detect early hearing loss. The procedure needs to 
be fast, simple, and able to select individuals with the 
highest probability of abnormal function26. Newborns 
in an neonatal ICU of the Caism/UNICAMP underwent 
hearing screening preferably before being discharged 
from the hospital; the procedures were automatic. 
A-BAEP has been recommended for use mainly in 
neonates in ICUs because of a higher incidence in this 
population of risk indicators for retrocochlear abnor-
malities involving inner hair cells, auditory pathways 
and/or the brainstem18,27.
Thirty-eight neonates failed the hearing screen-
ing, of which 25 (66%) were male and 50% were pre-
mature. Most of the children were male, which reflects 
the demography of most neonatal ICUs28.
All infants had at least one risk indicator in the 
clinical history (Table 1).
There was no statistically significant difference 
in normal and impaired hearing neonates in relation 
to the variables gender and number of risk indicators. 
On the other hand, term neonates were more affected 
by hearing loss than premature infants, and this finding 
was statistically significant (Table 1). Term neonates 
in this study required intensive care because of severe 
intercurrences at birth such as anoxia, congenital mal-
formation, syndromes, and congenital infection – all 
of which are risk indicators for hearing loss. Published 
studies describe neonatal features found in infants with 
hearing loss diagnosed by neonatal hearing screening, 
which includes gestational age over 37 weeks and birth 
at weight over 2,500 grams28.
Analysis of the tests showed that 42% (16/38) of 
children had normal results in all tests (Table 2). Their 
failure in hearing screening and normal auditory test 
results suggests either a temporary conduction type 
change in the auditory system that regressed, or delayed 
myelination of auditory pathways to the brainstem. 
 Normal hearing Hearing loss p-valuea
 n (%) n (%)  
SEX      
F 3 18.8 10 45.5  
M 13 81.3 12 54.6 0.867
No. of RI      
1 1 6.3 0 0  
2 8 50 13 59.1  
3 2 12.5 2 9.1  
3 or + 5 31.3 7 31.8 0.7403
GA      
PTN 11 68.8 8 36.4
TN 5 31.3 14 63.6 0.0487*
Table 1. Nursing infants that failed hearing screening, according 
to normal or impaired hearing and the variables sex, gestational 
age, and number of risk indicators.
a Fisher’s exact test / chi-square test.
RI: Risk indicators; GA: Gestational age.
PTN: Preterm newborn; TN: term newborn.
Diagnosis  Total
  N % N %
Normal hearing  16 42.2 16 42.2
Conductive loss Unilateral 2 5.2
Bilateral 10 26.3 12 31.5
Sensorineural loss Unilateral 1 2,6
Bilateral 9 23.7 10 26.3
Total  38 100 38 100
Table 2. Nursing infants that failed hearing screening, according 
to the audiologic and otorhinolaryngologic diagnosis.
 Environmental causes Genetic causes Total
Moderate 1 0 1
Severe 4 0 4
Profound 5 0 5
Total 10 0 10
Table 3. Nursing infants according to the grade and etiology 
of sensorineural hearing loss.
Table 1 shows the results for infants with normal 
or impaired hearing, related with the variables male/
female sex, indicators in the clinical history, and ges-
tational age.
Table 2 shows infants distributed according to the 
audiologic and otorhinolaryngologic diagnosis.
The 35delG mutation on the conexin 26 (GJB2) 
gene was not encountered, neither were the D(GJB6-
D13S1830) and ∆(GJB6-D13S1854) deletions on the 
GJB6 gene and the A1555G mutation on the MTRNR 
mitochondrial gene.
Table 3 presents infants with sensorineural hear-
ing loss, considering the grade and etiology.
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Infants with risk indicators in their clinical histories 
that might indicate progressive and/or late onset hear-
ing loss were referred for monitoring of hearing and 
language development.
Mostly bilateral conductive hearing loss was pres-
ent in 31.5% (12/38) of the sample (Table 2). Conductive 
hearing loss was present in 55% (12/22) of children. 
Audiological testing (BAEP) revealed absence of TOAE, 
type B tympanometric curve, absence of ipsilateral 
acoustic reflexes, and a normal auditory pathway at 80 
dB. We found that the Down syndrome was present in 
4 of 12 (33.33%) cases of conductive hearing loss; the 
external ear and the outer ear canal were malformed in 
one of the cases of unilateral conductive hearing loss.
Bone et al.29 published similar results showing 
conductive abnormalities in children that failed hear-
ing screening; the most common cause in these cases 
was otitis media. These abnormalities were variable, 
episodic, ranging from mild to moderate, never beyond 
50 dB30. Otitis media is highly prevalent in infancy, 
especially in high risk infants; middle ear secretions oc-
cur mostly between the 4th and 12th months, and occur 
least in the first three months of life30-33. It is multifac-
torial and associated with lack or early interruption of 
breastfeeding, feeding in decubitus, a first episode of 
acute otitis media before six months of age, immature 
or deficient immune system, stays in nurseries where 
common colds and the flu occur frequently, and passive 
smoking34. Infants presenting secretory otitis during the 
neonatal period are at a highest risk for chronic otitis 
media within the first year of life35. Studies on the oc-
currence and recurrence of middle ear secretion have 
shown a higher frequency of recurrences of four or 
more episodes in males; the highest incidence of middle 
ear secretion was in the first month of life. The authors 
also found that infants breastfed until 6 months of age 
had a higher recurrence rate – four or more episodes. 
The opposite was seen in infants nursed during more 
than 10 months. The authors recommended programs 
to prevent, diagnose, and treat otitis, especially because 
the first years of life are critical for development; they 
also suggested that healthcare professionals encourage 
breast feeding30.
Preventive measures, such as encouraging breast 
feeding, positioning the infants adequately while nurs-
ing, avoiding passive smoking, and other initiatives, 
may minimize conductive hearing losses. Such losses 
impair the development of hearing and language by 
causing sensory deprivation fluctuating hearing that is 
typical of otitis media.
The incidence of hearing loss in Down syndrome 
infants ranges from 2.6% to 67.5%; it has been attributed 
mainly to a high rate of secretory otitis media36,37. Strome 
et al.37 reported 70% middle ear effusion in 107 Down 
syndrome patients aged below 1 year. Several factors 
appear to increase the incidence of secretory otitis 
media, including: abnormal auditory tube anatomy, 
abnormal ossicular chain, dysfunction of muscles that 
open the auditory tube, and stenosis of the external 
acoustic meatus37.
These infants were receiving otorhinolaryngo-
logical treatment, periodic audiologic evaluations, and 
were monitored for language and hearing development. 
Published reports have shown that some cases of middle 
ear involvement resolve spontaneously without harm to 
development, whereas in other cases, the disease be-
comes chronic. In this case it may compromise language 
and educational development, and if left untreated, 
may progress and involve the mastoid cells or even 
the cranial cavity, which leads to serious complications 
including inner ear involvement and sensorineural 
hearing loss29,33.
We found sensorineural hearing loss in 28.9% 
(10/38) of the sample; five cases were moderate to 
severe, and five cases were profound loss (Table 3). 
These infants were referred for evaluation and fitting 
of hearing aids, guidance for parents, and phonoaudio-
logical rehabilitation. The most frequent risk indicators 
in the clinical histories were elevated blood bilirubin 
levels, perinatal anoxia and mechanical ventilation, and 
ICU stay for more than five days.
The results of three infants among the cases of 
bilateral profound sensorineural hearing loss were com-
patible with the auditory neuropathy spectrum disorder 
(ANSD), which consist of cochlear microphonism, ab-
sence of waves I, III, and V at 100 dB in BAEP testing, 
TOAE, a type A tympanometric curve, and absence 
of acoustic reflexes. An elevated bilirubin level was a 
risk indicator in the three cases – bilirubin levels were 
above 28 mg/dL.
Findings in the ANSD include 8th cranial nerve 
and/or brainstem dyssynchrony, disordered inner hair 
cells, dysfunctional spiral ganglion fibers38, abnormal 
synaptic afferent transmission between inner hair cells 
and the 8th cranial nerve39, and normally functioning out-
er hair cells. Most cases present bilateral abnormalities 
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ranging from severe to profound loss. However, uni-
lateral cases and moderate losses have been reported, 
which suggests an inhomogeneous entity40. The ANSD 
may occur in the absence of any other apparent medical 
condition; a history of elevated blood bilirubin levels 
in the perinatal period and asphyxia or anoxia is fre-
quent40. The ANSD is much more common in infants 
admitted into neonatal ICUs40. The reported prevalence 
in the literature ranges from 0.2% to 4% in infants at risk 
for hearing loss, and 0.5% to 15% in infants with known 
hearing loss40,41. The prevalence is lower in studies that 
enroll older children or those that study in schools for 
the deaf; it is possible that the ANSD is only diagnosed 
objectively in the first months of life when otoacoustic 
emissions are present because of normal outer hair cell 
function. As the disease progresses, these cells become 
inactive or may have been injured by hearing aids in 
undiagnosed infants. Declau et al.17 reported a diagnosis 
of ANSD in two cases (4.2%), one of which had elevated 
blood bilirubin levels in the perinatal period and the 
other had no risk indicators. It is important to make 
the differential diagnosis of sensorineural hearing loss 
because approaches will vary compared with measures 
taken to treat other forms of permanent hearing loss.
All study subjects were normal for the 35delG 
conexin gene 26 (GJB2) mutation. The V27I polymor-
phism on the GJB2 gene was found in subject 1 in 
heterozygosis, which is not relevant for hearing loss, 
as is the case for silent mutations. Although the 5delG 
mutation was not found in the sample after screening, 
it is extremely important since it is present in 70% of 
cases of deafness when the GJB2 gene is involved. 
The prevalence of carriers of the 35delG mutation in 
Brazil, as encountered in a survey of 620 neonates 
in Campinas (Sao Paulo state) is 0.97% – about 1:103 
heterozygotes42. A negative result for mutations in the 
GJB2 gene reduces the empirical risk of a genetic cause 
of deafness. Besides the GJB2 gene, ∆(GJB6-D13S1830) 
and ∆(GJB6-D13S1854) deletions on the GJB6 gene 
were also analyzed. None of our subjects had any of 
these deletions. We also tested for the A1555G mito-
chondrial mutation, which is associated with hearing 
loss and use of aminoglycoside antibiotics, and did 
not find this abnormality in any of our study subjects.
Declau et al.17 undertook a prospective study 
of audiological findings and causes of hearing loss in 
170 infants that failed neonatal hearing screening, of 
which 13 were admitted to the neonatal ICU. Infants 
that failed were referred for electrophysiologic testing 
(BAEP, stable state responses and/or behavioral tests). 
Permanent hearing loss was present in 61.5% of infants 
admitted to a neonatal ICU. The male to female ratio 
of hearing loss was 3/0. The mean hearing loss was 60 
dBHL. The most prevalent risk factors were mechanical 
ventilation, low weight, and elevated blood bilirubin 
levels. Environmental causes were the etiology in 39.6% 
of hearing loss cases; the most frequent was congenital 
cytomegalovirus infection (18.8% of cases).
According to the literature, the cause of hearing 
loss is genetic in 50% of cases and environmental in 
another 50% of cases in developed countries42,43. Also, 
the most important environmental factors for hearing 
loss are congenital infections, ototoxicity, prematurity, 
and neonatal anoxia43.
In our study, environmental factors in the his-
tory of infants were the most likely causes, because 
no genetic mutations commonly implicated in hearing 
loss were found (Table 3). Identifying the etiology of 
hearing loss is a relevant point that provides new infor-
mation for auditory rehabilitation, the prognosis, and 
the family. Furthermore, these studies may help clarify 
the epidemiological factors of hearing loss, which may 
support preventive and surveillance programs.
CONCLUSION
Analysis of audiologic, otorhinolaryngological, 
and genetic findings in high risk nursing infants that 
failed hearing screening showed that the frequency of 
hearing loss was higher in term neonates compared 
to premature neonates. Children with predominantly 
bilateral conductive and sensorineural hearing loss had 
a similar distribution. The likely causes of sensorineural 
hearing loss are environmental factors. The diagnosis 
and etiology of deafness are extremely important for 
establishing the prognosis and appropriate therapy.
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